An Innovative Antibody Discovery Workflow Leveraging Machine Learning to Prioritize Leads
![Omics-Tech-Spotlight_Webinar4_Laptop2 Omics-Tech-Spotlight_Webinar4_Laptop2](https://web.genewiz.com/hs-fs/hubfs/05-2023%20Genomics%20Innovation%20Spotlight/2024-02%20GEN%20-%20Technology%20Spotlight%20Webinar%20Series/Webinar%204%20-%20Antibody%20Discovery/Landing%20Page/Omics-Tech-Spotlight_Webinar4_Laptop2.png?width=400&height=242&name=Omics-Tech-Spotlight_Webinar4_Laptop2.png)
About the workshop
Antibody generation and validation can be time-consuming, taking up to 6-12 months using traditional screening and production methods. Even after a thorough antibody campaign, candidates often result in late-stage failure. In this webinar, explore how advancements to antibody screening methods can help you discover and develop your mAb therapies more quickly and efficiently, allowing you to generate a diverse list of antibody candidates for recombinant production with promising biophysical profiles for commercialization.
What you'll learn about
- The challenges of traditional antibody screening and production workflows
- Development of alternative technologies to increase speed, cost-effectiveness, antibody diversity, and more
- How high-throughput screening and computational approaches can generate 5-50x more antibody leads
Unable to attend live? Register today and we’ll send the recording to watch at your convenience.
About the presenter
![TechSeries_CrystalRichardson_500px](https://web.genewiz.com/hubfs/05-2023%20Genomics%20Innovation%20Spotlight/2024-02%20GEN%20-%20Technology%20Spotlight%20Webinar%20Series/Webinar%204%20-%20Antibody%20Discovery/TechSeries_CrystalRichardson_500px.png)
Crystal Richardson, Ph.D.
Senior Business Partnership Manager, Azenta Life Sciences
Dr. Crystal Richardson earned her Ph.D. from the University of Virginia with a degree in biomedical sciences. She has over six years of experience in molecular biology with a focus on clinical immunology. At Azenta, Dr. Richardson supports business operations and is our subject matter expert for adeno-associated virus (AAV) and recombinant antibody production.